Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rangering i aksjer #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Aksjekurs
$9.60
Sist synkronisert: 2025-05-21
Markedsverdi
$1.08B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel OptiNose, Inc. (OPTN)

Kategori

Inntekter for OptiNose, Inc. (OPTN)
Inntekter i Mar 2025 TTM: $-29.89M
Ifølge OptiNose, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-29.89M. I 2023 hadde selskapet et resultat på $-35.48M, en økning sammenlignet med resultatet i 2022, som var $-74.83M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for OptiNose, Inc. fra 2015 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-29.89M 38.76%
2024 $-21.54M -39.29%
2023 $-35.48M -52.58%
2022 $-74.83M -9.07%
2021 $-82.30M -17.53%
2020 $-99.79M -9.33%
2019 $-110.05M 3.18%
2018 $-106.66M 118.11%
2017 $-48.90M -316.26%
2016 $22.61M -179.87%
2015 $-28.31M 0.00%
Inntekter for lignende selskaper eller konkurrenter